Previous Close | 0.2700 |
Open | 0.2700 |
Bid | 0.2500 x N/A |
Ask | 0.2700 x N/A |
Day's Range | 0.2500 - 0.2700 |
52 Week Range | 0.2000 - 0.8500 |
Volume | |
Avg. Volume | 20,168 |
Market Cap | 9.58M |
Beta (5Y Monthly) | -0.01 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1600 |
Earnings Date | May 29, 2024 - Jun 03, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN “HYTN” or “The Company”), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds including cannabis, applauds the recent formal recommendation by the U.S. Justice Department, endorsed by the Drug Enforcement Agency (DEA), to reclassify cannabis from a Schedule I to a Schedule III controlled substance. This historic shift, pending revie
2023 Adjusted Revenue1 record revenue of $17.05 million, an increase of 102% compared to 2022.2023 GAAP revenue was $11.51 million an increase of 170% compared to 2022. 2023 gross margin of 43.11% compared to 43.00% in 2022.Q4, 2023 Adjusted Revenue1 of $4.99 million, an increase of 77% compared to Q4, 2022.Q4, 2023 GAAP revenue was $3.37 million an increase of 99% compared to Q4, 2022. Q4, 2023 gross margin of 46.54% compared to 43.77% in Q4, 2022Expanded service offering to over 700 cities acr
VANCOUVER, British Columbia, April 22, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0) “HYTN” or “The Company”, a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis, is pleased to announce significant advancements in its Good Manufacturing Practice (GMP) stability programs. Stability programs constitute a cornerstone of all GMP guidelines and are vital for achieving GMP certification.